LBH-589

Name: LBH-589
SKU: L0528
Availability: InStock

Product ID L0528

Cas No. 404950-80-7

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

LBH-589 (Panobinostat) is a hydroxamic acid inhibitor of class I (1, 2, 3, and 11) histone deacetylases (HDACs) that is clinically used to treat multiple myeloma and is currently in clinical trials as a potential treatment for other cancers. This compound displays anticancer chemotherapeutic and anti-metastatic activities. LBH-589 reverses the epithelial-to-mesenchymal transition (EMT), inhibits cell proliferation, invasion, and migration, and decreases tumor growth in animal models of breast cancer. In hepatocellular carcinoma cells, LBH-589 inhibits oncogenic miRNA expression and upregulates expression of APAF1 and Beclin-1.

Product Info

Cas No.	404950-80-7
Purity	≥98%
Formula	C₂₁H₂₃N₃O₂
Formula Wt.	349.43
IUPAC Name	(2E)-N-Hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Synonym	LBH589, Panobinostat
Solubility	DMSO 69 mg/mL (197.46 mM) Water Insoluble Ethanol Insoluble
Appearance	Off white powder

Shipping and Storage

Store Temp	-20°C
Ship Temp	Ambient

Downloads

MSDS	L0528 MSDS PDF
Info Sheet	L0528 Info Sheet PDF

References

Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol. 2014 Dec;5(6):197-210. PMID: 25469210.

Rhodes LV, Tate CR, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014 Jun;145(3):593-604. PMID: 24810497.

Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog. 2013 Dec 23. [Epub ahead of print]. PMID: 24375802.

Ovejero-Sanchez M, Gonzalez-Sarmiento R, Herrero AB. Synergistic effect of chloriquine and panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair. Neoplasia. 2021 May;23(5):515-528. PMID: 339930758.

Wilson A, Gupta V, Liu Q, et al. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. Neoplasia. 2022 Feb;24(2):63-75. PMID: 34933276.

Custom Order

Name*
First Last
Company/Institution
Email*
Enter Email Confirm Email
Product ID
Product Name
Unit Size
Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
Unit Label
Quantity
Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
Comments
Name
This field is for validation purposes and should be left unchanged.

LBH-589

Quicklinks

Description

Product Info

Shipping and Storage

Downloads

References

Custom Order

Related Products

Pseudoprotodioscin

10-Gingerol

Iberin

Urolithin C

Pyronaridine Tetraphosphate

Famotidine

Timolol Maleate

VS-4718

Clindamycin Palmitate Hydrochloride

Adenine

Orlistat

41-Oxo-rapamycin

Cefotaxime Acid

Meso-2,3-dimercaptosuccinic Acid

C-Type Natriuretic Peptide (1-22), human

LY-450139

TGR5 Receptor Agonist

Corosolic Acid

(±)-Jasmonic Acid

Sinomenine Hydrochloride

Footer